3 Active Ingredients and Custom Synthesis Leader, Global Generics Maker and Chronic Therapy Brand Leader Stocks With a Strong Future Roadmap: Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma

Ingredient, generics and brand pharma stocks offer a focused view of a sector where demand keeps widening. Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma cover an active ingredients and custom synthesis leader, a global generics maker and a chronic therapy brand leader.

This list covers three ingredient, generics and brand pharma stocks with complete current figures: Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Ingredient, Generics and Brand Pharma Stocks?

Ingredient, generics and brand pharma stocks are listed drug makers that supply ingredients to global buyers, sell generics abroad and market trusted brands to doctors in India. Their earnings depend on custom orders, product launches, plant quality and prescriptions.

Ingredient, Generics and Brand Pharma Stocks at a Glance

On valuation, Dr. Reddy's Laboratories trades at a P/E below the industry P/E, while Divi's Laboratories and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing ingredient, generics and brand pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Ingredient, Generics and Brand Pharma Stocks Have a Strong Roadmap in India?

Ingredient, generics and brand pharma stocks have a strong roadmap in India because growing healthcare access, global sourcing of ingredients and strong doctor networks keep lifting the revenue base.

• Custom synthesis. Global drug makers outsource complex molecules.
• Product pipeline. New launches widen reach in regulated markets.
• Doctor networks. A large field force helps brands scale.

Why Divi's Laboratories Features Among These Ingredient, Generics and Brand Pharma Stocks

Among the ingredient, generics and brand pharma stocks on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Dr. Reddy's Laboratories Features Among These Ingredient, Generics and Brand Pharma Stocks

Among the custom synthesis and US generics shares on this list, Dr. Reddy's Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.

Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.

The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.

Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.

Why Mankind Pharma Features Among These Ingredient, Generics and Brand Pharma Stocks

Among the three companies on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Divi's Laboratories vs Dr. Reddy's Laboratories vs Mankind Pharma on Key Financials

The table below sets the three ingredient, generics and brand pharma stocks side by side on revenue, profit and margin, using reported figures.

Divi's Laboratories posts the highest return on equity in this group at 15.3%. Dr. Reddy's Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Mankind Pharma shows the fastest revenue growth with a 16.4% compound annual rate. A useful habit with ingredient, generics and brand pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Ingredient, Generics and Brand Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these ingredient, generics and brand pharma stocks, the main points are: Long-term custom synthesis and US generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices abroad can fall.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter ingredient, generics and brand pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Ingredient, Generics and Brand Pharma Stocks

Ingredient, generics and brand pharma stocks reward patient research into demand, execution and financial strength. Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma each have a clear plan to grow. Based on the 26 October 2026 close, Divi's Laboratories trades at Rs 9,050, Dr. Reddy's Laboratories at Rs 1,310.9 and Mankind Pharma at Rs 2,312. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these ingredient, generics and brand pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track ingredient, generics and brand pharma stocks, set price alerts and get research-backed stock ideas.

What are ingredient, generics and brand pharma stocks?

Ans. Ingredient, generics and brand pharma stocks are listed drug makers that supply ingredients to global buyers, sell generics abroad and market trusted brands to doctors in India. Their earnings depend on custom orders, product launches, plant quality and prescriptions. This list looks at three of them, Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which ingredient, generics and brand pharma stocks are covered in this list?

Ans. This list covers Divi's Laboratories, Dr. Reddy's Laboratories and Mankind Pharma. Based on the 26 October 2026 close, Divi's Laboratories traded at Rs 9,050, Dr. Reddy's Laboratories at Rs 1,310.9 and Mankind Pharma at Rs 2,312. Their return on equity ranges from 11.1% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 16.4%.

Why do ingredient, generics and brand pharma stocks have a strong future roadmap in India?

Ans. Ingredient, generics and brand pharma stocks have a strong roadmap in India because growing healthcare access, global sourcing of ingredients and strong doctor networks keep lifting the revenue base. The main drivers are as follows. Custom synthesis. Global drug makers outsource complex molecules. Product pipeline. New launches widen reach in regulated markets. Doctor networks. A large field force helps brands scale. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Dr. Reddy's Laboratories performed financially?

Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What risks should investors check before buying ingredient, generics and brand pharma stocks?

Ans. Investors should check a few risks before buying ingredient, generics and brand pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of ingredient, generics and brand pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.